A Novel LC-MS/MS Method for Therapeutic Drug Monitoring of Baricitinib in Plasma of Pediatric Patients.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
25 Sep 2023
25 Sep 2023
Historique:
received:
28
02
2023
accepted:
13
05
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
aheadofprint
Résumé
Janus kinase inhibitors are antirheumatic immunosuppressive drugs that target intracellular Janus kinases (JAKs). Baricitinib is a selective and reversible orally administered JAK1/JAK2 inhibitor approved for treating rheumatoid arthritis, atopic dermatitis, and alopecia areata in adult patients. Expanded access to baricitinib has been approved for treating pediatric patients affected by rare Mendelian autoinflammatory diseases with type I interferon-mediated damage. Knowledge of the pharmacokinetic properties and target plasma levels of baricitinib in pediatric patients is limited. In this study, a novel LC-MS/MS method for measuring baricitinib in plasma, validated according to the ICH M10 guidelines, is presented. Sample preparation was performed by adding 10 µL of IS working solution (150 ng/mL) and 200 µL of MeOH to each plasma sample. Chromatographic separation was conducted using a Thermo Scientific Accucore Polar Premium column (50 mm × 2.1 mm, i.d. 2.6 m). This method was applied to 7 real anonymous plasma samples obtained from pediatric patients treated with baricitinib at IRCCS Istituto Giannina Gaslini (Genoa, Italy). Patients of both sexes had a median age of 14 years (range, 10-17 years). The LC-MS/MS method resulted linear over wide concentration ranges (1.024-100 ng/mL) and was accurate and reproducible in the absence of matrix effects, allowing for robust, specific, and rapid quantification of baricitinib from a low amount of plasma (50 µL). The plasma concentration of baricitinib in the samples of the patients, expressed as mean ± SD, was 11.25 ± 10.86 ng/mL. This novel LC-MS/MS method is suitable for the therapeutic drug monitoring of baricitinib and can help guide therapy optimization in pediatric patients.
Sections du résumé
BACKGROUND
BACKGROUND
Janus kinase inhibitors are antirheumatic immunosuppressive drugs that target intracellular Janus kinases (JAKs). Baricitinib is a selective and reversible orally administered JAK1/JAK2 inhibitor approved for treating rheumatoid arthritis, atopic dermatitis, and alopecia areata in adult patients. Expanded access to baricitinib has been approved for treating pediatric patients affected by rare Mendelian autoinflammatory diseases with type I interferon-mediated damage. Knowledge of the pharmacokinetic properties and target plasma levels of baricitinib in pediatric patients is limited. In this study, a novel LC-MS/MS method for measuring baricitinib in plasma, validated according to the ICH M10 guidelines, is presented.
METHODS
METHODS
Sample preparation was performed by adding 10 µL of IS working solution (150 ng/mL) and 200 µL of MeOH to each plasma sample. Chromatographic separation was conducted using a Thermo Scientific Accucore Polar Premium column (50 mm × 2.1 mm, i.d. 2.6 m). This method was applied to 7 real anonymous plasma samples obtained from pediatric patients treated with baricitinib at IRCCS Istituto Giannina Gaslini (Genoa, Italy). Patients of both sexes had a median age of 14 years (range, 10-17 years).
RESULTS
RESULTS
The LC-MS/MS method resulted linear over wide concentration ranges (1.024-100 ng/mL) and was accurate and reproducible in the absence of matrix effects, allowing for robust, specific, and rapid quantification of baricitinib from a low amount of plasma (50 µL). The plasma concentration of baricitinib in the samples of the patients, expressed as mean ± SD, was 11.25 ± 10.86 ng/mL.
CONCLUSIONS
CONCLUSIONS
This novel LC-MS/MS method is suitable for the therapeutic drug monitoring of baricitinib and can help guide therapy optimization in pediatric patients.
Identifiants
pubmed: 37752637
doi: 10.1097/FTD.0000000000001128
pii: 00007691-990000000-00149
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Lemaitre F, Solas C, Grégoire M, et al. Potential drug–drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundam Clin Pharmacol. 2020;34:530–547.
Markham A. Baricitinib: first global approval. Drugs. 2017;77:697–704.
Al-Salama ZT, Scott LJ. Baricitinib: a review in rheumatoid arthritis. Drugs. 2018;78:761–772.
European Medicines Agency (EMA). Olumiant. Version 25-May-2023. Available at. https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant#product-information-section. Accessed June 30, 2023.
Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54:1354–1361.
Zhang X, Chua L, Ernest C, et al. Dose/exposure-response modeling to support dosing recommendation for phase III development of baricitinib in patients with rheumatoid arthritis. CPT Pharmacometrics Syst Pharmacol. 2017;6:804–813.
Zhao X, Sheng XY, Payne CD, et al. Pharmacokinetics, safety, and tolerability of single- and multiple-dose once-daily baricitinib in healthy Chinese subjects: a randomized placebo-controlled study. Clin Pharmacol Drug Dev. 2020;9:952–960.
Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–662.
Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;23:60–61.
Kim H, Brooks KM, Tang CC, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther. 2018;104:364–373.
Montealegre Sanchez GA, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128:3041–3052.
Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinic. Trials. 2021;22:1–14.
A Study of Baricitinib (LY3009104) in Participants from 1 Year to Less Than 18 Years Old With sJIA. Available at: ClinicalTrials.gov.
A Study of Baricitinib in Participants from 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis. Available at: ClinicalTrials.gov.
A Study of Baricitinib in Participants from 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis. Available at: ClinicalTrials.gov.
European Medicines Agency (EMA). EMEA-001220-PIP01-11-M06. Version 12-April-2023. Available at. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001220-pip01-11-m06. Accessed June 30, 2023.
European Medicines Agency (EMA). Janus Kinase Inhibitors (JAKi). Version 22-May-2023. Available at. https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki. Accessed June 30, 2023.
Merienne C, Rousset M, Ducint D, et al. High throughput routine determination of 17 tyrosine kinase inhibitors by LC–MS/MS. J Pharm Biomed Anal. 2018;150:112–120.
Yu H, Steeghs N, Nijenhuis CM, et al. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53:305–325.
Herviou P, Thivat E, Richard D, et al. Therapeutic drug monitoring and tyrosine kinase inhibitors. Oncol Lett. 2016;12:1223–1232.
European Medicines Agency (EMA). ICH Guideline M10 on Bioanalytical Method Validation. EMA/CHMP/ICH/172948/2019. Version 25-July-2022. Available at. https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline. Accessed May 19, 2023.
Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019–3030.
Soldin OP, Soldin SJ. Review: therapeutic drug monitoring in pediatrics. Ther Drug Monit. 2002;24:1.
Barco S, Mesini A, Barbagallo L, et al. A liquid chromatography-tandem mass spectrometry platform for the routine therapeutic drug monitoring of 14 antibiotics: application to critically ill pediatric patients. J Pharm Biomed Anal. 2020;186:113273.
D'urso A, Cangemi G, Barco S, et al. LC-MS/MS-Based quantification of 9 antiepileptic drugs from a dried sample spot device. Ther Drug Monit. 2019;41:331–339.
Pigliasco F, Cafaro A, Simeoli R, et al. A UHPLC–MS/MS method for therapeutic drug monitoring of aciclovir and ganciclovir in plasma and dried plasma spots. Biomedicines. 2021;9:1379.
Cafaro A, Pigliasco F, Baiardi G, et al. Development and validation of a novel LC-MS/MS method for a TDM-guided personalization of HSCT conditioning with high-dose busulfan in children. Biomedicines. 2023;11:530.
Koller D, Vaitsekhovich V, Mba C, et al. Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. Talanta. 2020;208:120450.
Ezzeldin E, Iqbal M, Asiri YA, et al. A hydrophilic interaction liquid chromatography–tandem mass spectrometry quantitative method for determination of baricitinib in plasma, and its application in a pharmacokinetic study in rats. Molecules. 2020;25:1600.
Veeraraghavan S, Thappali SRS, Viswanadha S, et al. Simultaneous quantification of baricitinib and methotrexate in rat plasma by LC-MS/MS: application to a pharmacokinetic study. Sci Pharm. 2016;84:347–359.